EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis and Molecular Docking of New Thieno[2,3‑ d ]Pyrimidin‐4‐One Derivatives as Dual EGFR and FGFR Inhibitors

Sara Sultan iD, Samar S Tawfik, Khalid B Selim, Magda N A Nasr

Drug Development Research · 2025-02 · 86 (1)

DOI: 10.1002/ddr.70061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 06.02.2025. Verfasst von Sara Sultan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. Hauptthemen laut MEDLINE: ErbB Receptors, Drug Design, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel thienopyrimidinone hybrids 5–25 were developed and synthesized as potential inhibitors of human EGFR and FGFR. The in vitro antiproliferative action of all compounds, towards the human breast tumor cells MDA‐MB‐231 and MCF‐7, was evaluated with doxorubicin serving as a reference (IC 50 = 6.72 µM). Compound 23 demonstrated the highest anti‐breast cancer efficacy against both cellular lines having IC 50 ranging from 2.95 to 3.80 µM. The enzyme inhibition of human EGFR and FGFR by the most active candidates 18 , 21 and 23–25 was further evaluated. Compounds 21 and 25 were the best EGFR inhibitors having IC 50 values of 0.077 and 0.059 µM, respectively, in comparison to Erlotinib (IC 50 = 0.04 µM). In comparison with Staurosporine (IC 50 = 0.024 µM), compounds 24 and 25 were the most active FGFR inhibitors having IC 50 values of 0.055 and 0.029 µM, respectively. The study of molecular docking was carried out among the most active EGFR inhibitors 21 and 25 and the most active FGFR inhibitors 24 and 25 to examine the relation between the binding pattern of these compounds with EGFR and FGFR catalytic active sites and their biological activity, whereas the computational results were aligned with the biological results. Finally, compound 25 , which was found to be the best dual inhibitor against EGFR and FGFR, was tested for inducing apoptosis and affecting cellular arrest within G2/M phase as well as it was screened to measure its safety towards normal breast cells MCF10a with IC 50 value of 47.16 µM in contrast to the reference Staurosporine (IC 50 = 18.86 µM). Accordingly, compound 25 could be considered as a potential breast cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsDrug DesignAntineoplastic AgentsProtein Kinase InhibitorsReceptors, Fibroblast Growth FactorPyrimidinesHumansMolecular Docking SimulationCell ProliferationMCF-7 CellsCell Line, TumorBreast NeoplasmsFemaleStructure-Activity Relationship

Stichwörter der Autor:innen

EGFRFGFRbreast cancerthienopyrimidinone

Substanzen

ErbB ReceptorsEGFR protein, humanAntineoplastic AgentsProtein Kinase InhibitorsReceptors, Fibroblast Growth FactorPyrimidines

Autor:innen und Institutionen

  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.

ORCID-Profile: Sara Sultan

Zitieren

APA

Sultan, S., Tawfik, S. S., Selim, K. B., & Nasr, M. N. A. (2025). Design, Synthesis and Molecular Docking of New Thieno[2,3‑ d ]Pyrimidin‐4‐One Derivatives as Dual EGFR and FGFR Inhibitors. Drug Development Research, 86(1). https://doi.org/10.1002/ddr.70061

Vancouver

Sultan S, Tawfik SS, Selim KB, Nasr MNA. Design, Synthesis and Molecular Docking of New Thieno[2,3‑ d ]Pyrimidin‐4‐One Derivatives as Dual EGFR and FGFR Inhibitors. Drug Development Research. 2025;86(1). doi:10.1002/ddr.70061

BibTeX
@article{Sultan2025,
  author = {Sultan, Sara and Tawfik, Samar S and Selim, Khalid B and Nasr, Magda N A},
  title = {Design, Synthesis and Molecular Docking of New Thieno[2,3‑ d ]Pyrimidin‐4‐One Derivatives as Dual EGFR and FGFR Inhibitors},
  journal = {Drug Development Research},
  year = {2025},
  volume = {86},
  number = {1},
  doi = {10.1002/ddr.70061}
}
Kostenlos starten →